Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A spatially specified systems pharmacology therapy for axonal recovery after injury

MM. Siddiq, NP. Johnson, Y. Zorina, AS. Yadaw, CA. Toro, J. Hansen, V. Rabinovich, SM. Gregorich, Y. Xiong, RE. Tolentino, SS. Hannila, E. Kaplan, RD. Blitzer, MT. Filbin, CP. Cardozo, CL. Passaglia, R. Iyengar

. 2023 ; 14 (-) : 1225759. [pub] 20230920

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23022840

There are no known drugs or drug combinations that promote substantial central nervous system axonal regeneration after injury. We used systems pharmacology approaches to model pathways underlying axonal growth and identify a four-drug combination that regulates multiple subcellular processes in the cell body and axons using the optic nerve crush model in rats. We intravitreally injected agonists HU-210 (cannabinoid receptor-1) and IL-6 (interleukin 6 receptor) to stimulate retinal ganglion cells for axonal growth. We applied, in gel foam at the site of nerve injury, Taxol to stabilize growing microtubules, and activated protein C to clear the debris field since computational models predicted that this drug combination regulating two subcellular processes at the growth cone produces synergistic growth. Physiologically, drug treatment restored or preserved pattern electroretinograms and some of the animals had detectable visual evoked potentials in the brain and behavioral optokinetic responses. Morphology experiments show that the four-drug combination protects axons or promotes axonal regrowth to the optic chiasm and beyond. We conclude that spatially targeted drug treatment is therapeutically relevant and can restore limited functional recovery.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022840
003      
CZ-PrNML
005      
20240116163145.0
007      
ta
008      
240105s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2023.1225759 $2 doi
035    __
$a (PubMed)37799971
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Siddiq, Mustafa M $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
245    12
$a A spatially specified systems pharmacology therapy for axonal recovery after injury / $c MM. Siddiq, NP. Johnson, Y. Zorina, AS. Yadaw, CA. Toro, J. Hansen, V. Rabinovich, SM. Gregorich, Y. Xiong, RE. Tolentino, SS. Hannila, E. Kaplan, RD. Blitzer, MT. Filbin, CP. Cardozo, CL. Passaglia, R. Iyengar
520    9_
$a There are no known drugs or drug combinations that promote substantial central nervous system axonal regeneration after injury. We used systems pharmacology approaches to model pathways underlying axonal growth and identify a four-drug combination that regulates multiple subcellular processes in the cell body and axons using the optic nerve crush model in rats. We intravitreally injected agonists HU-210 (cannabinoid receptor-1) and IL-6 (interleukin 6 receptor) to stimulate retinal ganglion cells for axonal growth. We applied, in gel foam at the site of nerve injury, Taxol to stabilize growing microtubules, and activated protein C to clear the debris field since computational models predicted that this drug combination regulating two subcellular processes at the growth cone produces synergistic growth. Physiologically, drug treatment restored or preserved pattern electroretinograms and some of the animals had detectable visual evoked potentials in the brain and behavioral optokinetic responses. Morphology experiments show that the four-drug combination protects axons or promotes axonal regrowth to the optic chiasm and beyond. We conclude that spatially targeted drug treatment is therapeutically relevant and can restore limited functional recovery.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Johnson, Nicholas P $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States $u Departments of Chemical and Biomedical Engineering, University of South Florida, Tampa, FL, United States $u National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center, New York, NY, United States
700    1_
$a Zorina, Yana $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Yadaw, Arjun Singh $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Toro, Carlos A $u National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center, New York, NY, United States $u Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Hansen, Jens $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Rabinovich, Vera $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Gregorich, Sarah M $u Departments of Chemical and Biomedical Engineering, University of South Florida, Tampa, FL, United States
700    1_
$a Xiong, Yuguang $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Tolentino, Rosa E $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Hannila, Sari S $u Department of Human Anatomy and Cell Science, Basic Medical Sciences Building, Winnipeg, NM, United States
700    1_
$a Kaplan, Ehud $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States $u Department of Philosophy of Science, Prague and the National Institute of Mental Health, Charles University, Prague, CZ, United States
700    1_
$a Blitzer, Robert D $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Filbin, Marie T $u Department of Biological Sciences, Hunter College, City University of New York, New York, NY, United States
700    1_
$a Cardozo, Christopher P $u National Center for the Medical Consequences of Spinal Cord Injury, James J. Peters VA Medical Center, New York, NY, United States $u Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States $u Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
700    1_
$a Passaglia, Christopher L $u Departments of Chemical and Biomedical Engineering, University of South Florida, Tampa, FL, United States
700    1_
$a Iyengar, Ravi $u Department of Pharmacological Sciences, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 14, č. - (2023), s. 1225759
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37799971 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240116163142 $b ABA008
999    __
$a ok $b bmc $g 2036415 $s 1209285
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1225759 $e 20230920 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20240105

Find record

Citation metrics

Archiving options